Argus analyst David Toung raised the firm’s price target on Cencora (COR) to $280 from $270 and keeps a Buy rating on the shares. The company delivered strong results for Q1 and expects topline ...

Cencora, formerly known as AmerisourceBergen, is one of the Big 3 drug distributors alongside peers McKesson Corporation (MCK) and Cardinal Health, Inc. (CAH). It provides pharmaceutical ...

Moody's downgrades Walgreens outlook to negative Judge orders Walgreens to pay nearly $1 billion in COVID test case Walgreens injecting $300M in another Cencora sell-off, early settlement ...

Cencora has a solid industry position in an oligopolistic market with supernormal return ratios and solid stock price returns. 1QFY25 results, as well as the near-term outlook, are also solid ...

Chesterbrook, PA-based Cencora is one of the world’s largest pharmaceutical services companies, which focuses on providing drug distribution and related services to reduce health care costs and ...

Cencora, Danaher and McKesson. He also holds stock in tech companies Alphabet, Amazon, Apple, Meta, Microsoft and Nvidia as well as healthcare startups. His assets are worth anywhere from $95 ...

But on the bright side, you can make far more than 100% on a really good stock. Long term Cencora, Inc. (NYSE:COR) shareholders would be well aware of this, since the stock is up 156% in five years.

Healthcare and pharmaceuticals have the second largest exposure. Distributors such as McKesson Corp. and Cencora Inc. could face disruption, with the analysts noting government spending is related ...

Cencora has a 12-month low of $214.77 and a 12-month high of $262.26. The company has a market capitalization of $47.71 billion, a PE ratio of 35.11, a price-to-earnings-growth ratio of 1.49 and a ...